$GNSZ Headlines GenSpera executes funding 10:3
Post# of 102254
Posted On: 07/14/2014 1:14:57 PM
$GNSZ Headlines
GenSpera executes funding 10:30 a.m. May 29, 2014 - Seeking Alpha
10-Q: GENSPERA INC 5:08 p.m. May 12, 2014 - Edgar Online - (EDG = 10Q, 10K)
10-K: GENSPERA INC 7:08 a.m. March 3, 2014 - Edgar Online - (EDG = 10Q, 10K)
10-Q: GENSPERA INC 3:37 p.m. Aug. 14, 2013 - Edgar Online - (EDG = 10Q, 10K)
Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 9:20 a.m. Today - PR Newswire - PRF
Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 8:00 a.m. Today - PR Newswire - PRF
GenSpera To Present Ongoing HCC Trial Data at APPLE 2014 Congress July 12th in Taipei 8:00 a.m. July 7, 2014 - PR Newswire - PRF
Media Advisory: GenSpera 2014 BIO International Presentation Available 8:00 a.m. June 30, 2014 - PR Newswire - PRF
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity 8:15 a.m. June 25, 2014 - PR Newswire - PRF
GenSpera Releases 2014 BIO International Presentation and HCC Clinical Trial Update for G-202 4:27 p.m. June 24, 2014 - PR Newswire - PRF
GenSpera Releases 2014 BIO International Presentation and HCC Clinical Trial Update for G-202 2:30 p.m. June 24, 2014 - PR Newswire - PRF
GenSpera, Inc. (GNSZ) Releases Updated Corporate Video: "GenSpera has targeted its active ingredient thapsigargin to kill only the cells we select: cancer" 8:00 a.m. June 23, 2014 - PR Newswire - PRF
A New Breed of Targeted Cancer Therapeutics & Stem Cell Advancements; Effective ProDrug Therapeutics Approach for GenSpera 8:29 a.m. June 20, 2014 - PR Newswire - PRF
GenSpera CEO, Craig Dionne, to Present Update on Lead Drug Candidate G-202 at 2014 Bio International Convention 8:00 a.m. June 19, 2014 - PR Newswire - PRF
GenSpera Announces $3.33 Million Registered Public Offering 8:54 a.m. May 29, 2014 - BusinessWire - BZX
IPOs and Transactions: March 17 - 21 12:30 p.m. March 24, 2014 - PR Newswire - PRF
First Patient Enrolled in GenSpera G-202 Phase II Glioblastoma Trial 8:03 a.m. March 18, 2014 - BusinessWire - BZX
GenSpera CEO, Craig Dionne, to Present at BIO CEO & Investor Conference, February 10th 10:02 a.m. Feb. 6, 2014 - BusinessWire - BZX
GenSpera CEO to Present at New York Society of Security Analysts' Life Sciences Conference 8:02 a.m. Oct. 28, 2013 - BusinessWire
Final Phase I Data on GenSpera's G-202 Presented at Symposium on Molecular Targets and Cancer Therapeutics 8:02 a.m. Oct. 22, 2013 - BusinessWire
GenSpera G-202 Principal Investigator Presents Phase I Data at Symposium on Molecular Targets and Cancer Therapeutics 8:02 a.m. Oct. 17, 2013 - BusinessWire
GenSpera Receives Patent on Targeted Prostate Cancer Drugs 8:02 a.m. June 6, 2013 - BusinessWire
GenSpera executes funding 10:30 a.m. May 29, 2014 - Seeking Alpha
10-Q: GENSPERA INC 5:08 p.m. May 12, 2014 - Edgar Online - (EDG = 10Q, 10K)
10-K: GENSPERA INC 7:08 a.m. March 3, 2014 - Edgar Online - (EDG = 10Q, 10K)
10-Q: GENSPERA INC 3:37 p.m. Aug. 14, 2013 - Edgar Online - (EDG = 10Q, 10K)
Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 9:20 a.m. Today - PR Newswire - PRF
Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 8:00 a.m. Today - PR Newswire - PRF
GenSpera To Present Ongoing HCC Trial Data at APPLE 2014 Congress July 12th in Taipei 8:00 a.m. July 7, 2014 - PR Newswire - PRF
Media Advisory: GenSpera 2014 BIO International Presentation Available 8:00 a.m. June 30, 2014 - PR Newswire - PRF
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity 8:15 a.m. June 25, 2014 - PR Newswire - PRF
GenSpera Releases 2014 BIO International Presentation and HCC Clinical Trial Update for G-202 4:27 p.m. June 24, 2014 - PR Newswire - PRF
GenSpera Releases 2014 BIO International Presentation and HCC Clinical Trial Update for G-202 2:30 p.m. June 24, 2014 - PR Newswire - PRF
GenSpera, Inc. (GNSZ) Releases Updated Corporate Video: "GenSpera has targeted its active ingredient thapsigargin to kill only the cells we select: cancer" 8:00 a.m. June 23, 2014 - PR Newswire - PRF
A New Breed of Targeted Cancer Therapeutics & Stem Cell Advancements; Effective ProDrug Therapeutics Approach for GenSpera 8:29 a.m. June 20, 2014 - PR Newswire - PRF
GenSpera CEO, Craig Dionne, to Present Update on Lead Drug Candidate G-202 at 2014 Bio International Convention 8:00 a.m. June 19, 2014 - PR Newswire - PRF
GenSpera Announces $3.33 Million Registered Public Offering 8:54 a.m. May 29, 2014 - BusinessWire - BZX
IPOs and Transactions: March 17 - 21 12:30 p.m. March 24, 2014 - PR Newswire - PRF
First Patient Enrolled in GenSpera G-202 Phase II Glioblastoma Trial 8:03 a.m. March 18, 2014 - BusinessWire - BZX
GenSpera CEO, Craig Dionne, to Present at BIO CEO & Investor Conference, February 10th 10:02 a.m. Feb. 6, 2014 - BusinessWire - BZX
GenSpera CEO to Present at New York Society of Security Analysts' Life Sciences Conference 8:02 a.m. Oct. 28, 2013 - BusinessWire
Final Phase I Data on GenSpera's G-202 Presented at Symposium on Molecular Targets and Cancer Therapeutics 8:02 a.m. Oct. 22, 2013 - BusinessWire
GenSpera G-202 Principal Investigator Presents Phase I Data at Symposium on Molecular Targets and Cancer Therapeutics 8:02 a.m. Oct. 17, 2013 - BusinessWire
GenSpera Receives Patent on Targeted Prostate Cancer Drugs 8:02 a.m. June 6, 2013 - BusinessWire
(0)
(0)Scroll down for more posts ▼